The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
C | Cardiovascular system | |
2
|
C01 | Cardiac therapy | |
3
|
C01A | Cardiac glycosides |
| Code | Title | |
|---|---|---|
| C01AA | Digitalis glycosides | |
| C01AB | Scilla glycosides | |
| C01AC | Strophantus glycosides | |
| C01AX | Other cardiac glycosides |
| Active Ingredient |
|---|
|
|
|
|
|
Digoxin increases contractility of the myocardium by direct activity. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+ - K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect. |
|
|
|
Metildigoxin, a methyl derivative of digoxin, is a cardiac glycoside a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia. |
| Document | Type | Information Source | |
|---|---|---|---|
| Lanoxin 125 Tablets | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| LANOXIN Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| LANOXIN Tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |